Can-Fite Biopharma Ltd., of Petach Tikva, Israel, said it is set to start patient enrollment in the second quarter for its phase III trial testing lead candidate piclidenoson, an A3 adenosine receptor agonist, as a first-line treatment for rheumatoid arthritis.